The alarms have been going on for months in the offices of the European Center for Disease Prevention and Control (ECDC). The agency’s latest data reveals that sexually transmitted infections (STDs) have reached their peak highest level in more than a decade … within the continent. The balance is devastating: diagnoses of gonorrhea have skyrocketed by 303% since 2015 and those of syphilis have more than doubled in the same period. Chlamydia is consolidated as the most common infection with more than 213,000 cases annually.
«Sexually transmitted infections lead ten years on the rise. If left untreated, they can cause serious complications, such as chronic pain and infertility,” Bruno Ciancio, head of the ECDC’s Directly Transmitted and Vaccine Preventable Diseases Unit, warned last month.
This rebound, fueled by the lack of homogeneous access to diagnostic tests and by behavioral changes after the pandemichits women of reproductive age especially hard. In fact, cases of congenital syphilis, transmitted directly from mother to fetus, have practically doubled since last year.
Faced with this scenario, the search for solutions has become a pressing task.
The reproductive tract bunker
The answer could be in the mucosal immunizationa frontier that until now had proven extremely elusive for researchers. For decades, the design of an effective vaccine against diseases such as genital herpes has been one of the greatest challenges for virology. Herpes simplex virus type 2 (HSV-2) is entrenchment in the reproductive tractan area of difficult immunological access, given that the body itself tends to naturally slow down its defenses to avoid collateral damage and harmful inflammation in the tissue.
Now, a team of American researchers seems to have found the key to bypassing this biological blockade. According to a study published this Friday in the journal ‘Science Immunology’, they have developed custom-designed nanoparticles that act as a molecular “beacon”, massively attracting defense cells to the vaginal mucosa without unleashing a dangerous local inflammatory storm.
The adjuvant enigma
Previous attempts to stimulate the defenses in this area using powerful synthetic stimulators managed to reduce the virus load, but at the cost of provoking an inflammatory response so aggressive that it was unviable for application in humans. The new approach camouflages and enhances these stimuli through high-precision biochemical combination in animal models.
To solve the puzzle, the engineer Sachin Bhagchandani and their colleagues at the Massachusetts Institute of Technology (MIT) and Yale University developed an adjuvant—the component of vaccines responsible for “awakening” the immune system—baptized with the acronym BEACON (bioactively enhanced chemokine oligonucleotide nanoparticles). The system combines CpG DNA molecules with CXCL9, a cell signaling protein that acts as a forceful recruitment agent for lymphocytes.
A permanent quartering
The strategy was tested in mice using a mixed two-phase system. First, the animals received a dose of conventional preparation intramuscularly to present the virus’s glycoproteins to the body. Subsequently, reinforcement was applied directly intravaginally which combined the same proteins with the BEACON adjuvant.
The results showed that these nanoparticles dramatically improved enemy capture by antigen-presenting cells. Thanks to this “beacon,” CD8 T lymphocytes flocked to the vaginal mucosa and stayed there permanently as resident memory cells. This local retention of the defenses made the fundamental difference.
When comparing the mice protected with the adjuvant against the control group that only received the classic vaccine boosters, the animals treated with the new platform their local antibodies multiplied and maintained a much deeper and longer reduction in viral load over time.
Shielding against other STDs
The implications of this advance go far beyond herpes and offer a window of hope to stop the health crisis detailed by the ECDC, and which of course also affects our country. Having demonstrated that it is possible to educate the immune system so that strictly monitor a mucosa Without breaking anything in the process, the authors hope that the mechanism will serve as a kind of template applicable to other STDs that lack effective vaccines.
«Our findings offer a strategy against other pathogens: HIV-1, human papillomavirus or chlamydia»
“Our findings offer a generalizable strategy to direct the response against other sexually transmitted pathogens, including HIV-1, human papillomavirus or chlamydia, in which mucosal immunity is essential but is hardly induced by other types of vaccines,” Bhagchandani and the rest of the authors detail in the conclusions of the article.
The jump from mice to the first clinical trials will determine whether science is, finally, at the beginning of the end of one of the most elusive families of chronic infections on the planet.
